Search results
Found 2280 matches for
A multi-disciplinary Institute within the University of Oxford which focuses upon translational activities to catalyse the discovery of new medicines.
Medicinal Chemistry
The Med Chem Group supports the CMD Pillars to select druggable targets, and discover and optimise small molecule leads.
Protein Crystallography (PX)
The focus of our research is the establishment of methods to ensure that X-ray structures can serve as a routine and predictive tool for generating novel chemistry for targeting proteins. This focus area includes both early development of leading-edge technologies and approaches, and crucially deployment into definable platforms
Research Informatics
The Research Informatics group, led by Prof. Brian Marsden, focuses on driving the research informatics, data management and research computing capabilities and needs at the Centre for Medicines Discovery (CMD).
Membrane Protein Structural and Chemical Biology
Understanding the mechanisms of membrane enzymes, their mechanism of pathogenesis, and enabling their targeting by new therapeutics.
Mass Spectrometry for Drug Target Discovery
Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development.
Growth Factor Signalling and Ubiquitination
Our research aims to understand the signalling mechanisms and disease-causing mutations that alter cell growth and differentiation and how these might be targeted by small molecule inhibitors to address devastating rare diseases and cancer.
Chemical Biology
To boldly explore any protein where no drug has gone before.
Cellular Signalling
We aim to understand the proteins that transmit signals within the cell and the signalling pathways that regulate the cell’s functions. Understanding these pathways and proteins enables the discovery of new drug targets for treating disease.
High Throughput Screening
The HTS facility provides Oxford research scientists and collaborators access to a comprehensive, cost-effective facility for running high throughput cell based small compound and CRISPR screens across a broad range of readouts.
BRC Translational Science Team
Our overarching goal is to accelerate the development of novel medicines for patients. We are a multidisciplinary team, funded by the NIHR Oxford Biomedical Research Centre (BRC), catalyzing the translation of small molecule inhibitors into clinical candidates for early stage clinical trials. We establish partnerships to maximise innovation, learning and new avenues for translation through close collaboration with clinicians, academics, and a range of external partners.
The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI)
The Alzheimer's Research UK Oxford Drug Discovery Institute couples the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies.